NDUFS4 and Cachexia: As noted, treatment with pexidartinib prevented both cachexia and hypoglycemia in the Ndufs4(KO) mice in a dose-dependent manner (Figure 3, H–J) (5), consistent with leukocytes playing a role in metabolic derangements.